about
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaMarine low molecular weight natural products as potential cancer preventive compoundsBOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated DegradationNF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy targetThe p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitinationAntimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3BFoxM1 is a general target for proteasome inhibitors.Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells.Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophiesNovel treatments for cancer cachexia.Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation.BAX/BAK-independent mitoptosis during cell death induced by proteasome inhibition?Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastomaThe ubiquitin-proteasome system and assays to determine responses to inhibitors.Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver diseaseThe protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitorsTreatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in miceNew betulinic acid derivatives as potent proteasome inhibitorsAntibody-mediated rejection: an evolving entity in heart transplantation.Seven-transmembrane receptors and ubiquitinationSubstituted quinolines as noncovalent proteasome inhibitors.Palau'amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasomeProteasome inhibitors in mantle cell lymphomaViral defense, carcinogenesis and ISG15: novel roles for an old ISGEffect of NF-κB inhibitors on the chemotherapy-induced apoptosis of the colon cancer cell line HT-29.A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.Minireview: ubiquitination-regulated G protein-coupled receptor signaling and traffickingImmunodeficiency and immunotherapy in multiple myeloma.Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.Targeting the ubiquitin-proteasome system for cancer therapyInhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genesCell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cellsEssential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.The Mechanistic Links Between Proteasome Activity, Aging and Age-related Diseases.A new target for proteasome inhibitors: FoxM1FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesisHumoral immunotherapy of multiple myeloma: perspectives and perplexities.
P2860
Q24643447-3151922C-D220-4362-A4C1-079612629F7CQ27025660-09ADBD7F-8EEB-4323-A615-5E95F7268DABQ28593563-0F64F739-E752-4A84-8BF2-2559F4CB4C3CQ28611413-96FE0492-23AD-487D-B536-EB4CD9FB2CC0Q28743328-B93C703D-A717-449C-8E5C-DB9A290637B7Q33303627-E86BBD74-858E-44B6-A859-5C967EF6A55DQ33492774-B87893FE-B65C-4959-8E69-818FFEFD0B04Q33557490-3D601685-70A9-4044-A3F5-9EF12AC8DA60Q33745227-C5786DF0-70FF-48B1-BA22-F98291DA65FCQ34005616-EEB8F300-AC71-4DAC-A3BD-480E0A7B1656Q34053359-436E71EE-8AE7-4C60-861B-052C658057A9Q34082489-E4B91A89-B726-40FE-B96C-714621E69B64Q34205125-77115DB7-4B60-49EC-8191-DAB0C63EF864Q34347848-CC8C2AEC-6246-4034-A02F-77F45A8A5DD7Q34514734-37ABC6F2-07E5-43E3-932F-B283D18F31F3Q34731408-C1751F00-6B2D-4AB2-9B15-1B9F430712F4Q35065984-11EA620C-549D-4D7B-B28D-ECB77221FA6FQ35146262-76044B4D-4381-418C-BBAF-BDBBCA1E5B45Q35175035-448CAFEE-BC14-4B22-B251-6773682657ACQ35209514-5DA624D6-78E9-4A40-B096-24BD5969EF58Q35876250-E8F6CD1F-8E29-456F-835A-9577C0F8FC1EQ35951259-7DDDC3F0-2A43-4F67-A09D-0F8FF0A151D9Q35998619-5E321387-23E4-4D20-A26E-A62421BFB1B4Q36008590-9FE78283-5540-41E4-8AAC-4F46B19892E7Q36028745-F9B9F24A-6449-4CAC-9215-2361AD1734D4Q36065915-5F3BFA09-3B8D-424E-8285-2D51391734E0Q36409305-C22C9F10-9F5A-4532-A426-5C70EFB24A66Q36520182-549FDFCD-E53C-40F2-8559-A0CFC125BE07Q36714881-34AD3437-9C1F-4819-B151-DEAFCF962DB4Q36904977-7812E171-B253-4E03-AAA1-1AAE2A6D55A5Q36984165-BC000001-ECC3-4B0D-A6C1-7E7F80E23985Q37084564-51FC8579-B5EC-4603-AE6F-728D4E42D764Q37098481-63339B9D-5285-4DBE-ACAD-063ED6478AABQ37110640-43485FA0-8ACB-45A9-8404-7C8CC3D8F137Q37204538-8518986C-C24E-4306-83EA-060318EA09F5Q37446487-4A1EDB5F-F3C1-4A30-B010-D50CA509D171Q37645630-3CB5C69C-E53F-48DE-B6F2-5B3A9716DD19Q37674617-237300E5-ABBB-4C8D-A602-B34EE4E79BBBQ37716906-4C908C5D-CF01-45F2-8C8C-844F992CFFC0Q37724368-C0123795-AFED-463B-9448-1C77ED854778
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Proteasome inhibitors: antitumor effects and beyond.
@ast
Proteasome inhibitors: antitumor effects and beyond.
@en
type
label
Proteasome inhibitors: antitumor effects and beyond.
@ast
Proteasome inhibitors: antitumor effects and beyond.
@en
prefLabel
Proteasome inhibitors: antitumor effects and beyond.
@ast
Proteasome inhibitors: antitumor effects and beyond.
@en
P2093
P2860
P356
P1433
P1476
Proteasome inhibitors: antitumor effects and beyond.
@en
P2093
Ballestrero A
Brossart P
Grünebach F
Nencioni A
P2860
P2888
P356
10.1038/SJ.LEU.2404444
P577
2006-11-09T00:00:00Z